Log in

GRI GRI Bio, Inc. NASDAQ · United States

GRI Bio (GRI) news GRI going concern, offering and Nasdaq notice news

Latest GRI Bio news

  1. Company Updates

    GRI Bio receives FDA orphan drug designation for GRI-0621 in IPF

    The FDA granted orphan drug designation to GRI-0621 for idiopathic pulmonary fibrosis, a designation that could bring seven years of U.S. market exclusivity if the drug is approved.

  2. Company Updates

    GRI Bio reports first-quarter 2026 results and new GRI-0621 data

    GRI Bio reported approximately $11.0 million in cash as of March 31, 2026, and added analyses from its Phase 2a trial of GRI-0621 in idiopathic pulmonary fibrosis.

  3. Listings

    GRI Bio says Nasdaq found it conditionally regained stockholders' equity compliance

    Nasdaq's staff found only conditional compliance with the $2.5 million equity rule after a December 2025 deficiency notice. The company's auditors had already raised going-concern doubt in its 2024 annual report.

  4. Listings

    GRI Bio gets Nasdaq deficiency notice on minimum stockholders' equity requirement

    Nasdaq told GRI Bio on November 26, 2025 that it does not meet the $2,500,000 stockholders' equity requirement for the Capital Market. The company has until January 10, 2026 to submit a compliance plan, and its annual report already carried a going-concern warning.

  5. Financings

    GRI Bio prices $5.0 million public offering at $3.60 with three warrant series

    The prospectus puts gross proceeds at $4,999,878 and says auditors have raised going-concern doubt. Cash covers operations into the third quarter of 2025 with the money.

GRI Bio annual financials

LineFY2025FY2024
Research and development$6.8 million$3.8 million
Net income (loss)-$12.0 million-$8.2 million
Cash from operations-$10.2 million-$8.6 million
Cash and equivalents$8.2 million$5.0 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $10.9 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about GRI Bio

Has GRI Bio issued a going-concern warning?

Our latest story on this, dated Jan 16, 2026: "GRI Bio says Nasdaq found it conditionally regained stockholders' equity compliance". The story links the filing or release it is based on. Read the story.

Has GRI Bio raised money recently?

Our latest story on this, dated Mar 25, 2025: "GRI Bio prices $5.0 million public offering at $3.60 with three warrant series". The story links the filing or release it is based on. Read the story.

Has GRI Bio received a Nasdaq deficiency notice?

Our latest story on this, dated Jan 16, 2026: "GRI Bio says Nasdaq found it conditionally regained stockholders' equity compliance". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of GRI Bio?

GRI Bio, Inc. trades under the ticker GRI on NASDAQ.

Where is GRI Bio listed?

GRI Bio, Inc. is listed on NASDAQ.

What is the SEC CIK of GRI Bio?

The SEC Central Index Key (CIK) for GRI Bio, Inc. is 1824293. Its filings are on SEC EDGAR.

How many shares does GRI Bio have outstanding?

2,186,115 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is GRI Bio listed under?

Our directory records GRI Bio, Inc. under United States.

What does GRI Bio do?

Our directory classifies GRI Bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of GRI Bio?

The ISIN recorded for GRI Bio, Inc. is US3622AW5029.

Does aibio.space cover GRI Bio?

aibio.space lists GRI Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is GRI Bio incorporated?

SEC records list its state or country of incorporation as DE.

Is GRI Bio profitable?

GRI Bio, Inc. reported a net loss of $12.0 million for the fiscal year ended Dec 31, 2025, and used $10.2 million of cash in operations, per its annual report to the SEC.

How much does GRI Bio spend on research and development?

$6.8 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does GRI Bio have?

$10.9 million in cash at Jun 30, 2026, per its 10-Q.

Investor discussion: GRI Bio

Members talk about GRI Bio (GRI). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at GRI Bio, newest first. Each line links the filing it comes from.

  1. Financings

    Reported a financing. SEC Form S-3. Source

  2. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source

  3. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  4. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). Source

  5. Financings

    Reported a financing. SEC Form 424B5. Source

  6. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  7. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  8. Financings

    Reported a financing. SEC Form S-1. Source

  9. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  10. Legal

    Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source

  11. Financings

    Reported a financing. SEC Form S-1. Source

  12. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source

  13. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source

  14. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source

  15. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  16. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  17. Financings

    Set up an at-the-market program to sell shares over time. SEC Form S-3. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:GRI on TradingView.

SEC filings and registration

SEC name
GRI Bio, Inc.
CIK
1824293
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
GRI (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037
Phone
(619) 400-1171
Shares outstanding
2,186,115 as of 2026-08-13 (10-Q filed 2026-08-14)
Former names
Vallon Pharmaceuticals, Inc.

Recent filings (8-K and 6-K are the company's own announcements)

  • DEF 14A filed 2026-09-28
  • 8-K filed 2026-09-08
  • 10-Q filed 2026-08-14
  • 8-K filed 2026-06-18
  • 8-K filed 2026-05-14
  • 10-Q filed 2026-05-13
  • 8-K filed 2026-02-04
  • 10-K filed 2026-01-30

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

GRI Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GRI, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
GRI Bio, Inc.
Ticker
GRI
Listing
NASDAQ
Country or territory
United States
Business scope
Biotechnology
ISIN
US3622AW5029
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.